Virax Biolabs updates warrant exercise, share count
Virax Biolabs Group Limited reports that all 12,500,000 pre-funded warrants issued in a prior private placement have now been exercised.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Virax Biolabs Group Limited reports that all 12,500,000 pre-funded warrants issued in a prior private placement have now been exercised. That private placement raised gross proceeds of $5,000,000 through pre-funded warrants and preferred investment options sold at $0.3999 per unit. Following the exercises, the company’s ordinary shares outstanding total 19,923,432 as of April 10, 2026.
Key Figures
Private placement proceeds: $5,000,000
Pre-funded warrants issued: 12,500,000 warrants
Preferred options issued: 12,500,000 options
+4 more
7 metrics
Private placement proceeds
$5,000,000
Gross proceeds from December 3, 2025 private placement
Pre-funded warrants issued
12,500,000 warrants
Pre-funded warrants to purchase ordinary shares in the offering
Preferred options issued
12,500,000 options
Preferred investment options to purchase ordinary shares
Unit purchase price
$0.3999 per unit
Price per pre-funded warrant and associated preferred option
Pre-funded warrant exercise price
$0.0001 per share
Exercise price for each ordinary share under pre-funded warrants
Preferred option exercise price
$0.40 per share
Exercise price for ordinary shares under preferred options
Shares outstanding
19,923,432 shares
Ordinary shares outstanding as of April 10, 2026
Key Terms
pre-funded warrants, preferred investment options, private placement offering, accredited investor, +1 more
5 terms
pre-funded warrants financial
"in consideration of (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 12,500,000 ordinary shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
preferred investment options financial
"and (ii) preferred investment options to purchase up to 12,500,000 Ordinary Shares (the “Preferred Options”)"
Preferred investment options are choices that typically offer a safer and more stable way to grow or protect your money, often providing consistent returns or income. They matter to investors because they can help balance risk and reward, serving as a reliable foundation in an investment portfolio—similar to choosing a well-established route over a risky shortcut.
private placement offering financial
"entered into a securities purchase agreement with an accredited investor for a private placement offering"
A private placement offering is when a company sells its stock or bonds directly to a small group of investors instead of offering them to the general public. This allows the company to raise money quickly and privately, often for specific projects or needs, without going through a public stock exchange.
accredited investor financial
"entered into a securities purchase agreement with an accredited investor (the “Purchaser”)"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
registration statement regulatory
"for a period of five years from the date of effectiveness of the registration statement referred to below"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Virax Biolabs (VRAX) disclose in its April 2026 Form 6-K?
Virax Biolabs disclosed that all 12,500,000 pre-funded warrants issued in a prior private placement have been exercised. As a result, the company’s ordinary shares outstanding increased to 19,923,432 as of April 10, 2026, updating investors on its current share count.
How much capital did Virax Biolabs (VRAX) raise in the private placement?
Virax Biolabs raised gross proceeds of $5,000,000 in the private placement completed on December 3, 2025. The capital came from selling pre-funded warrants and preferred investment options to an accredited investor at $0.3999 per combined unit, before fees and expenses.
What securities were issued in Virax Biolabs’ (VRAX) private placement?
The private placement included pre-funded warrants to purchase 12,500,000 ordinary shares and preferred investment options to purchase up to 12,500,000 ordinary shares. Both instruments were sold together at a purchase price of $0.3999 per pre-funded warrant and associated preferred option unit.
What are the terms of Virax Biolabs’ (VRAX) pre-funded warrants?
Virax Biolabs’ pre-funded warrants have an exercise price of $0.0001 per ordinary share, are exercisable commencing on the issuance date and do not expire. As of April 10, 2026, all 12,500,000 pre-funded warrants issued in the private placement have been fully exercised.
What are the key terms of Virax Biolabs’ (VRAX) preferred investment options?
The preferred investment options allow the holder to purchase up to 12,500,000 ordinary shares at an exercise price of $0.40 per share. They become exercisable immediately upon issuance and remain exercisable for five years from the date the related registration statement becomes effective.
AI-generated analysis. How Rhea-AI works. Not financial advice.
